24/7 Market News Snapshot 23 June, 2025 – Fractyl Health, Inc. Common Stock (NASDAQ:GUTS)

June 23, 2025

DENVER, Colo., 23 June, 2025 (www.247marketnews.com) – (NASDAQ:GUTS) are discussed in this article.
Fractyl Health, Inc. (GUTS) is witnessing a bearish trend in trading, with shares currently priced at $2.058—a decline of 3.83% from the previous close of $2.140. The trading volume has reached 1.52 million shares, indicating heightened activity among investors. This downward movement raises concerns about potential further declines, prompting a close monitoring of key support levels, while resistance around the previous close could offer a short-term rebound opportunity.

In parallel, Fractyl Health has reported promising three-month results from the REVEAL-1 Cohort of its pivotal REMAIN-1 study, focusing on its revolutionary treatment, Revita. These results indicate that Revita may significantly aid individuals in maintaining or even losing weight after halting GLP-1 therapies traditionally used for obesity management.

Among the 13 participants who achieved over 15% weight loss through GLP-1 medications, an impressive 12 preserved their weight or continued to lose weight following a single Revita procedure. Noteworthy is that six participants reported additional weight loss, illustrating Revita’s potential as a viable, drug-free method for weight maintenance. The median weight change was a stable 0.46%, contrasting sharply with the common scenario where individuals experience a 5-6% weight regain after discontinuing GLP-1 treatments.

Dr. Shelby Sullivan, a prominent figure in metabolic health, underscored the significant need for effective strategies that allow patients to cease GLP-1 use while avoiding weight regain. The tolerability of Revita has remained impressive, with mild, transient side effects reported and no serious unexpected adverse effects.

Fractyl Health aims to share further findings from ongoing studies, including additional data from the Midpoint Cohort in Q3 2025. With Revita, the company is setting a new standard in metabolic therapeutics, addressing obesity and establishing groundwork for long-term weight management solutions.

Related news for (GUTS)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.